Biomedical subjects

Juan Zhou

Publications and source records attributed to Juan Zhou.

22 records · Page 2Linked to original sources

PubMed2003

Action of NO and TNF-alpha release of rats with cadmium loading in malfunctiion of multiple system organ.

Thirty-six healthy Sprague-Dawley male rats were used and divided randomly into a control group (group C), a medium-dose cadmium loading group (group M) and a high-dose cadmium loading group (group H). Cadmium chloride was diluted with saline to contain 0.4 mg/ml of autoclaved cadmium solution. Groups M and H were injected in the abdominal cavity with 0.5 and 1.0 mg of cadmium per kg body weight respectively, and group C with saline of the same dosage as in group H over 7 d. Six rats of each group were killed on the 4th day and 7th day after cadmium loading, respectively, and blood, testis, liver and heart were collected. Cadmium content, changes in nitric oxide and tumor necrosis factor-alpha were studied in blood and the tissues of testis, liver and heart. Results showed that during the entire experimental period, body weight in groups M and H decreased significantly as compared with that in group C; cadmium concentration increased significantly in testis, heart and liver of groups M and H, and rose with increased dosage and time of cadmium loading; there was no obvious difference in plasma nitric oxide between groups M and C, though nitric oxide was higher in group M than in group C. Nitric oxide in group H was significantly superior to that in group C. Plasma tumor necrosis factor-alpha was markedly higher in groups M and H than in group C. Nitric oxide contents in the rat s testis, liver and heart homogenates with cadmium loading were higher than those in group C or significantly superior to group C. The same changes in tumor necrosis factor-alpha in the tissue homogenates of the testis and heart were found, but no obvious difference in tumor necrosis factor-alpha in the liver between the three groups was observed. It is suggested that the massive release of nitric oxide and tumor necrosis factor-alpha induced by cadmium loading may play an important role in the induction of malfunction of multiple systems or organs in rats.

Animals↗

PubMed2003

Comparative study of serum lipids and serum lipoprotein spectrum in patients with cerebrovascular diseases.

OBJECTIVE: To investigate the differences of serum lipids and serum lipoprotein spectrum between patients with cerebral hemorrhage (CH) and cerebral infarction (CI), and study their features of expression in the 2 cerebral conditions. METHODS: Serum levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), very-low-density lipoprotein cholesterol (vLDLC), low-density lipoprotein cholesterol (LDLC) and serum lipoprotein electrophoretogram were determined in 59 CI and 21 CH patients as well as in 30 normal subjects. RESULTS: CI patients had higher levels of TC, LDLC, alpha-lipoprotein (alpha LP), beta-lipoprotein (beta LP) and intermediate-density beta-lipoprotein (int beta LP) than the normal subjects, and the CH patients had lower LDLC level than the CI patients. The CH patients had also higher levels of beta LP, int beta LP and LDLC than the normal subjects. Progressive regression analysis was performed and resulted in the selection of beta LP, int beta LP and HDLC as the best discriminators for cerebral vascular diseases, which were valid in classifying 71.3% of the cases included in this study. CONCLUSION: beta LP, int beta LP and HDLC are important clinical indicators to predict cerebral vascular diseases.

Aged↗

PubMed2002

[Effects of chronic cadmium loading on the testis and endocrine function of reproduction in male rats].

Sixty healthy Sprague-Dawley male rats were used and divided randomly into control group (group C), cadmium loading group with medium dose (group M) and cadmium loading group with high dose (group H). Groups C, M and H were orally dosed daily with 0, 5 and 10 mg/kg of cadmium for over 6 weeks. Effects of cadmium loading on testis and endocrine function of reproduction in male rats were studied. The results showed that the zinc content decreased slightly in testis and plasma, and the cadmium concentration increased significantly in the testis of groups M and H; while the plasma levels of cadmium and zinc had no obvious difference as compared with those of group C; daily sperm production in the testis of group H decreased markedly during week 3 of cadmium loading, and was significantly lower in groups M and H as compared to that in group C during week 6; alkaline phosphatase (ALP) in group H and lactate dehydrogenase-X (LDH-X) in groups M and H were markedly lower compared to those of group C; plasma testosterone (T) level in both cadmium loading groups decreased and was low or significantly lower than that in group C; follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels had no apparent difference between the three groups. It is suggested that the gradual accumulation of cadmium in testis tissue induced by chronic cadmium loading results in changes in some enzyme activity, a decrease in sperm production, and defect of endocrine function activity in the testis.

Alkaline Phosphatase↗

PubMed2002

[Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].

BACKGROUND AND OBJECTIVE: Cancer chemotherapy can induce thrombocytopenia. It is necessory to develop drugs that can prevent and treat thrombocytopenia. The current study was designed to evaluate the efficacy and toxicity of rhIL-11 in prevention and treatment of chemotherapy-induced thrombocytopenia. METHOD: A total of 109 cancer patients were involved randomly into AB or BA group and every patient received 2 cycles of chemotherapy. IL-11 was administered subcutaneously(50 micrograms/kg/d), beginning 24 hours after completion of chemotherapy for 14 consecutive days or continuing until platelet count was > 400 x 10(9)/L during cycle A. Patients did not received IL-11 during cycle B. Another 41 cases of cancer patients whose platelet were less than 50 x 10(9)/L after chemotherapy entered into open study group. IL-11 administration was the same as above. RESULTS: Efficacy can be evaluated in 107 cases in controlled study group. Mean platelet count of cycle A was (246.49 +/- 88.64) x 10(9)/L and cycle B was (180.24 +/- 83.34) x 10(9)/L(P = 0.000). Grade III/IV thrombocytopenia in cycle A and cycle B were 7/107(6.5%) and 15/107(14%), respectively (P = 0.04). The minimum platelet counts were (136.46 +/- 74.64) x 10(9)/L and (107.77 +/- 61.33) x 10(9)/L, respectively (P = 0.000). The maximum platelet counts were (381.28 +/- 150.39) x 10(9)/L and (207.44 +/- 113.32) x 10(9)/L, respectively (P = 0.000). For open study group, 32 patients could be evaluated. The platelet count increased from(30.1875 +/- 12.13) x 10(9)/L to (226.25 +/- 163.91) x 10(9)/L after IL-11 administration. Major adverse effects were edema, dizziness, palpitation, etc. CONCLUSION: rhIL-11 can reduce thrombocytopenia induced by chemotherapy and is a safe and effective drug for treatment of thrombocytopenia.

Adult↗